

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

Calu-3

RRID:CVCL_0609

Type: Cell Line

Proper Citation

RRID:CVCL_0609

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0609

Proper Citation: RRID:CVCL_0609

Description: Cell line Calu-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:327080](#), [PMID:3129183](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3940644](#), [PMID:6220172](#), [PMID:7459858](#), [PMID:7515578](#), [PMID:9636188](#), [PMID:10523844](#), [PMID:11064206](#), [PMID:15463957](#), [PMID:17483357](#), [PMID:18083107](#), [PMID:19153074](#), [PMID:19472407](#), [PMID:20090954](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24207061](#), [PMID:25485619](#), [PMID:25555374](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:34339474](#), [PMID:35839778](#), [PMID:35879413](#)

Comments: Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Calu-3

Synonyms: CaLu-3, CALU-3, Calu 3, Calu3, CALU3

Cross References: BTO:BTO_0002750, CLO:CLO_0002192, EFO:EFO_0002819, CLDB:cl634, CLDB:cl635, CLDB:cl5176, Abcam:ab275465, AddexBio:C0016001/30, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-55, BCRJ:0264, BioGRID_ORCS_Cell_line:1375, BioSample:SAMN03471552, BioSample:SAMN10988517, cancercellines:CVCL_0609, CancerTools:161906, CCRID:1101HUM-PUMC000032, CCRID:1101HUM-PUMC000329, CCRID:3101HUMTCHu157, CCRID:4201HUM-CCTCC00647, Cell_Model_Passport:SIDM00922, ChEMBL-Cells:ChEMBL3307390, ChEMBL-Targets:ChEMBL614534, CLS:305032, Cosmic:687777, Cosmic:910562, Cosmic:933578, Cosmic:945227, Cosmic:961842, Cosmic:1006532, Cosmic:1028940, Cosmic:1146873, Cosmic:1219068, Cosmic:1239869, Cosmic:1434969, Cosmic:1802295, Cosmic:2125219, Cosmic:2664117, Cosmic:2772161, Cosmic-CLP:687777, DepMap:ACH-000392, EGA:EGAS00001000610, EGA:EGAS00001002554, GDSC:687777, GEO:GSM108803, GEO:GSM108804, GEO:GSM159355, GEO:GSM159356, GEO:GSM159357, GEO:GSM159358, GEO:GSM253347, GEO:GSM353233, GEO:GSM434276, GEO:GSM513948, GEO:GSM514318, GEO:GSM784249, GEO:GSM794262, GEO:GSM817064, GEO:GSM827549, GEO:GSM886915, GEO:GSM887981, GEO:GSM1374433, GEO:GSM1374434, GEO:GSM1669658, IARC_TP53:21264, IGRhCellID:Calu3, IZSLER:BS TCL 103, KCB:KCB 202003YJ, KCLB:30055, LiGeA:CCL_462, LINCS_HMS:50010, LINCS_LDP:LCL-1631, Lonza:342, MetaboLights:MTBLS762, MetaboLights:MTBLS2352, MetaboLights:MTBLS2840, Millipore:SCC438, PharmacDB:Calu3_179_2019, PRIDE:PRD000594, PRIDE:PXD000589, PRIDE:PXD019645, PRIDE:PXD023418, PRIDE:PXD023422, PRIDE:PXD023760, PRIDE:PXD024242, PRIDE:PXD024375, PRIDE:PXD024883, PRIDE:PXD025499, PRIDE:PXD026302, PRIDE:PXD030304, PRIDE:PXD034135, Progenetix:CVCL_0609, PubChem_Cell_line:CVCL_0609, TOKU-E:768, Wikidata:Q52392355

ID: CVCL_0609

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260815T231957+0000

Ratings and Alerts

No rating or validation information has been found for Calu-3.

No alerts have been found for Calu-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1642 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pasquero S, et al. (2026) Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. *iScience*, 29(3), 115038.

Xu Y, et al. (2026) KCTD10 weakens m6A modification of IL-11 in a ubiquitin-dependent manner to repress tumour immune escape in lung adenocarcinoma. *British journal of pharmacology*, 183(16), 4778.

Criscuolo E, et al. (2026) miR-29a and miR-15b Modulate SARS-CoV-2 Beta and Omicron Infection in Human Lung Epithelial Cells. *International journal of molecular sciences*, 27(13).

Te Marvelde MR, et al. (2026) Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies. *NPJ vaccines*, 11(1), 25.

Chen W, et al. (2026) Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation. *Life sciences*, 394, 124357.

Rae B, et al. (2026) Accessible Silicone Chip-to-Membrane Sealing Procedure for Flexible, Reliable Bonding. *Journal of visualized experiments : JoVE*(229).

Wang BL, et al. (2026) Multi-Omics reveals SPP1 + malignant and CXCR4+ TAM crosstalk predicts immunotherapy response in lung adenocarcinoma. *Discover oncology*, 17(1).

Huang P, et al. (2026) Plasma - Activated medium engages redox signaling to activate a VDAC1-TRPML1 lysosomal-mitochondrial Ca²⁺ death pathway. *Free radical biology & medicine*, 253, 622.

Kong W, et al. (2026) Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. *Journal of virology*, 100(4), e0027026.

Shi G, et al. (2026) Uridine cytidine kinase 1 promotes phosphatidylcholine biosynthesis, facilitating SARS-CoV-2 infection. *Molecular cell*.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Minnecci M, et al. (2026) Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. *ChemMedChem*, 21(1), e202501000.

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Chen N, et al. (2026) Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4. Journal of virology, 100(5), e0028226.

Wacharapluesadee S, et al. (2026) Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia. Cell, 189(13), 4075.

Posch W, et al. (2025) Aloe-derived polysaccharides (APS) mitigate SARS-CoV-2 Omicron BQ1.1 infection by preserving epithelial integrity and reducing viral load in human airway epithelial (HAE) cultures. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 192, 118657.

Lu Z, et al. (2025) Automated Label-Free Assay for Viral Detection and Inhibitor Screening via Biomembrane-Functionalized Microelectrode Arrays. Advanced materials (Deerfield Beach, Fla.), e01985.

Wang X, et al. (2025) HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. BMC cancer, 25(1), 1317.